Introduction: Gastroenteropancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of tumors. Octreotide is used in the symptom control of NETs. The PROMID study demonstrated a benefit of octreotide on disease stabilization in midgut NETs, but a survival analysis was not possible due to insufficient events.
Aim(s): To determine if dose of octreotide correlates with outcomes.
Materials and methods: We reviewed all patients who were diagnosed between 1987-2013 and treated with octreotide at the BC Cancer Agency. We compared overall survival in patients who received low v. high dose octreotide.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Sally C M Lau
To read results and conclusion, please login ...
Further abstracts you may be interested in